 <p>FORM PTO-1289 OCT 10 2003 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)</p>	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. ABGENIX.030C1	APPLICATION NO. 10/660,357
	APPLICANT Bar-Eli et al.			
	FILING DATE September 10, 2003		GROUP Not assigned	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
DB	1.	4,735,210	04/05/98	Goldenberg	128	654	
	2.	5,101,827	04/07/92	Goldenberg	128	653.4	
	3.	5,102,990	04/07/92	Rhodes	520	391.5	
	4.	5,648,471	07/15/97	Buttram et al.	424	1.49	
DB	5.	5,697,901	12/16/97	Eriksson	604	46	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
DB	6.	Anfosso et al., "Activation of Human Endothelial Cells via S-Endo-1 Antigen (CD146) Stimulates the Tyrosine Phosphorylation of Focal Adhesion Kinase p125 ^{FAK} ," <i>J. Bio. Chem.</i> , 273(41):26852-26856 (1998)
	7.	Bani et al., "Multiple Features of Advanced Melanoma Recapitulated in Tumorigenic Variants of Early Stage (Radial Growth Phase) Human Melanoma Cell Lines: Evidence for a Dominant Phenotype ¹ ," <i>Cancer Res.</i> , 56:3075-3086 (1996)
	8.	Bar-Eli, M., "Role of AP-2 in tumor growth and metastasis of human melanoma," <i>Cancer and Metastasis Reviews</i> , 18:377-385 (1999)
	9.	Frankel et al., "Cell Surface Receptor-Targeted Therapy of Acute Myeloid Leukemia: A Review," <i>Cancer Biotherapy & Radiopharmaceuticals</i> , 15(5):459-476 (2000)
	10.	Hedrick et al., "The DCC gene product in cellular differentiation and colorectal tumorigenesis," <i>Genes & Development</i> , 8:1174-83 (1994)
	11.	Holzmann et al. "Tumor Progression in Human Malignant Melanoma: Five Stages Defined by Their Antigenic Phenotypes," <i>Int. J. Cancer</i> , 39:466-471 (1987)
DB	12.	Jean et al., "Regulation of tumor growth and metastasis of human melanoma by the CREB transcription factor family," <i>Molecular and Cellular Biochemistry</i> , 212:19-28 (2000)


EXAMINER



DATE CONSIDERED


9/10/04

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

 <p>FORM PTO-1399</p> <p>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(USE SEVERAL SHEETS IF NECESSARY)</p>	ATTY. DOCKET NO. ABGENIX.030C1	APPLICATION NO. 10/660.357
	APPLICANT Bar-Eli et al.	
	FILING DATE September 10, 2003	GROUP Not assigned

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
DB	13 Johnson, J.P., "Cell adhesion molecules in the development and progression of malignant melanoma," <i>Cancer and Metastasis Reviews</i> , 18: 345-357 (1999)
	14 Johnson, J.P. et al., "Melanoma Progression-Associated Glycoprotein MUC18/MCAM Mediates Homotypic Cell Adhesion Through Interaction with a Heterophilic Ligand," <i>Int. J. Cancer</i> , 73:769-774 (1997)
	15 Junghans et al., <i>Cancer Chemotherapy and Biotherapy: Principals and Practice</i> , pgs. 655-689 (2d ed., Chabner and Longo, eds., Lippincott Raven 1996)
	16 Knoll et al., "Targeted Therapy of Experimental Renal Cell Carcinoma with a Novel Conjugate of Monoclonal Antibody 138H11 and Calicheamicin θ^1 ," <i>Cancer Res.</i> , 60:6089-6094 (2000)
	17 Lai et al., "Two forms of 1B236/myelin-associated glycoprotein, a cell adhesion molecule for postnatal neural development, are produced by alternative splicing," <i>Proc. Natl. Acad. Sci. USA</i> , 84:4337-4341 (1987)
	18 Lehmann, J.M. et al., "Discrimination Between Benign and Malignant Cells of Melanocytic Lineage by Two Novel Antigens, a Glycoprotein with a Molecular Weight of 113,000 and a Protein with a Molecular Weight of 76,000 ¹ " <i>Cancer Res.</i> , 47:841-845 (1987)
	19 Lehmann, J.M. et al. "MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neutral cell adhesion molecules of the immunoglobulin superfamily," <i>Proc. Natl. Acad. Sci. USA</i> , 86:9891-9895 (1989)
	20 Liu et al., "Eradication of large colon tumor xenografts by targeted delivery of maytansinoids," <i>Proc. Natl. Acad. Sci. USA</i> , 93:8618-8623 (1996)
	21 Luca, M. "Direct correlation between MUC18 expression and metastatic potential of human melanoma cells," <i>Melanoma Res.</i> , 3:35-41 (1993)
	22 Mandler et al., "Immunoconjugates of Geldanamycin and Anti-HER2 Monoclonal Antibodies: Antiproliferative Activity on Human Breast Carcinoma Cell Lines," <i>J. Natl. Cancer Inst.</i> , 92(19):1573-1581 (2000)
	23 Ota et al., "Antitumor effect of monoclonal antibody-carboplatin conjugates in nude mice bearing human ovarian cancer cells," <i>Int. J. Clin. Oncol.</i> , 4:236-240 (1999).
	24 Owens et al., "Organization of the neural cell adhesion molecule (N-CAM) gene: Alternative exon usage as the basis for different membrane-associated domains," <i>Proc. Natl. Acad. Sci. USA</i> , 84:294-298 (1987)
	25 Pickl, W.F. et al., "MUC18/MCAM (CD146), An Activation Antigen of Human T Lymphocytes," <i>J. Immunol.</i> , 158:2107-2115 (1997)
	26 Pourquie et al., "BEN, a surface glycoprotein of the immunoglobulin superfamily, is expressed in a variety of developing systems," <i>Proc. Natl. Acad. Sci. USA</i> , 89:5261-5265 (1992)
	27 Satyamoorthy, K. et al., "Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication," <i>Oncogene</i> , 20:4676-4684 (2001)
	28 Schlagbauer-Wadl, et al., "Influence of MUC18/MCAM/CD146 expression on human melanoma growth and metastasis in scid mice," <i>Int. J. Cancer</i> , 81:951-955 (1999)
	29 Sers et al., Genomic organization of the melanoma-associated glycoprotein MUC18: Implications for the evolution of the immunoglobulin domains," <i>Proc. Natl. Acad. Sci. USA</i> , 90:8514-8518 (1993)
V	30 Sers et al., "MUC18, a Melanoma-Progression Associated Molecule, and Its Potential Role in Tumor Vascularization and Hematogenous Spread ¹ ," <i>Cancer Research</i> , 54:5689-5694 (1994)
DB	31 Shih et al., "Expression of melanoma cell adhesion molecule in intermediate trophoblast," <i>Lab. Invest.</i> , 75(3):377-388 (1996)

EXAMINER <i>Daniel Blahut</i>	DATE CONSIDERED <i>9/10/04</i>
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	



FORM PTO-122

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ABGENIX.030C1APPLICATION NO.
10/660,357INFORMATION DISCLOSURE STATEMENT
BY APPLICANT


(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Bar-Eli et al.FILING DATE
September 10, 2003GROUP
Not assigned

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
DB	32.	Shih et al., "Isolation and Functional Characterization of the A32 Melanoma-associated Antigen ¹ ," <i>Cancer Res.</i> , 54:2514-2520 (1994)
	33.	Shih et al., "The Cell-Cell Adhesion Receptor Mel-CAM Acts As a Tumor Suppressor in Breast Carcinoma," <i>Am. J. Pathol.</i> , 151(3):745-751 (1997)
	34.	Shih et al., "Melanoma Cell-Cell Interactions Are Mediated Through Heterophilic Mel-CAM/Ligand Adhesion ¹ ," <i>Cancer Res.</i> , 57:3835-3840 (1997)
	35.	Shih et al., "Diagnostic and Biological Implications of Mel-CAM Expression in Mesenchymal Neoplasms," <i>Clinical Cancer Res.</i> , 2:569-575 (1996)
	36.	Taira et al., "Molecular Cloning and Functional Expression of Gicerin, a Novel Cell Adhesion Molecule That Binds Neurite Outgrowth Factor," <i>Neuron</i> , 12: 861-872 (1994)
DB	37.	Xie et al., "Expression of MCAM/MUC18 by Human Melanoma Cells Leads to Increased Tumor Growth and Metastasis ¹ ," <i>Cancer Res.</i> , 57:2295-2303 (1997)

S:\DOCS\SRG\SRG-2103.DOC\100203Vvo

EXAMINER <i>David Blahut</i>	DATE CONSIDERED <i>9/10/04</i>
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 809; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT	



FORM PTO-149

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ABGENIX.030C1APPLICATION NO.
10/660,357INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Bar-Eli et al.FILING DATE
September 10, 2003GROUP
Not Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
JB	1. Higuchi et al., Cyclic AMP Enhances the Expression of an Extravillous Trophoblast Marker, Melanoma Cell Adhesion Molecule, in Choriocarcinoma Cell JEG3 and Human Chorionic Villous Explant Cultures," <i>Molecular Human Reproduction</i> , 9: 359-366 (2003)

S:\DOCS\SRG\SRG-2210.DOC\110303Vvo

EXAMINER	<i>Edward Blahut</i>	DATE CONSIDERED	9/10/04
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. ABGENIX.030C1	APPLICATION NO. 10/860,357
	APPLICANT Bar-Eli et al.	
	FILING DATE September 10, 2003	GROUP Not Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
DB	1.	US 2003/0068319 A1	04/10/03	Bar-Eli			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

EXAMINER INITIAL	

S:\DOCS\SRG\SRG-2515.DOC\021104\vo

EXAMINER <i>Paul Blahut</i>	DATE CONSIDERED <i>9/10/04</i>
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	